trial

A First In Human Study Of PF-00184562 In Healthy Volunteers

NCTId NCT00150215
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 18
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
18
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Double
Start
2005-07
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
PF-00184562Olanzapine

Sponsors

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.Lead Sponsor
PPD Development, LPCollaborator

Sites

1 total
Austin, United States

Facts & assertions

3 sourced
Enrollment
18
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
PF-00184562
drug
Olanzapine
drug
lead_sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
collaborator
PPD Development, LP
company
indication
Schizophrenia
indication
Schizophrenia
indication